The Spanish bet against cancer

2024-09-24 00:53:00

World Cancer Research Day

Pharmamar is the Spanish group that invests the most in research and development (R&D) in relation to its sales

PHARMAMAR

Cancer is the main cause of death in Spain; It is estimated that by 2024 more than 285,000 new cases will be diagnosed. Worldwide, 18.1 million cases were found in 2020, and it is expected that by 2040 the number will reach 28 million annually. This increase, which is partly linked to factors such as the age of the population and changes in lifestyle habits, requires an urgent need to improve prevention and early detection strategies.

Also, one of the biggest challenges lies in develop more effective treatments that not only combat the disease, but also increase survival rates.

Ideally, raising awareness about the importance of cancer research is the goal of World Cancer Research Daywhich we do every year on September 24. The culture of collaborative research is important to enable more people to be diagnosed earlier and treated more effectively, with an improvement in the quality of life at all levels.

Cancer research is the only key to changing the disease and giving new options to patients. In Spain, we know this, in fact, among others, we stand out as the first European country to conduct clinical trials to test the safety and effectiveness of new drugs and we are in countries Europe’s top 10 countries have the most families of the world’s patents on cancer used for the last decade.

In the same sense, companies ‘made in Spain’ make great efforts and contributions to oncological research with the aim of changing cancer treatment. It is a case of PharmaMarA Spanish company with a global reach that has established itself as a world leader in the research and development of water-based oncological drugs. His new method is based on the principle of marine invertebratesThe development of complex defense mechanisms throughout evolution, provides a rich source of natural compounds with considerable therapeutic potential.

PharmaMar has the world’s largest collection of aquatic organisms, with more than 400,000 samples collected in more than 200 trips to 35 countries. In addition, the company stands for Spanish company that invests the most in research and development (R&D) in relation to its sales, according to the 2023 report «2023 EU R&D Industry Investment Level» of the European Council. In 2023, it allocates 83.6 million euros to oncology research, with an increase of 30% compared to the previous year.

rare disease

PharmaMar has focused much of its efforts on rare diseases, such as soft tissue sarcoma, multiple myeloma, and small cell lung cancer. Soft tissue sarcoma represents only 1% of adult cancers, making it a significant challenge. Multiple myeloma, which is rare, is the second most common blood cancer in the world, while small cell lung cancer does not have many treatment options, representing 15% of all lung cancers.

Thanks to his rigorous research work, PharmaMar has developed Three drugs are approved to treat these types of diseasesas well as eggs. In addition, it has received 22 orphan drug designations worldwide, demonstrating its commitment to developing new treatments for rare diseases with unmet medical needs.

Report a bug